circTUBD1-hnRNPK Regulates the Proliferation and Migration of LSCC by Targeting CCAR1

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-03-25 DOI:10.1002/cam4.70834

Yufeng Xu, Shijie Qiu, Zhisen Shen, Jingjing Chen

{"title":"circTUBD1-hnRNPK Regulates the Proliferation and Migration of LSCC by Targeting CCAR1","authors":"Yufeng Xu, Shijie Qiu, Zhisen Shen, Jingjing Chen","doi":"10.1002/cam4.70834","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Laryngeal squamous cell carcinoma (LSCC) is one of the most prevalent malignancies of the head and neck region. Circular RNAs (circRNAs) have been found to exhibit abnormal expression patterns in various tumors and play pivotal roles in tumorigenesis and tumor progression.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Functional assays assessed proliferation, migration, and invasion. Mechanistic studies were performed to explore the interaction between circTUBD1 and heterogeneous nuclear ribonucleoprotein K (hnRNPK), as well as its regulation of Cell Cycle and Apoptosis Regulator 1 (CCAR1). In vivo experiments confirmed circTUBD1's role in tumor growth and metastasis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We discovered that circTUBD1 is significantly upregulated in LSCC and promotes the proliferation, invasion, and migration of LSCC cells. circTUBD1 forms a circRNA-protein complex with hnRNPK and facilitates LSCC progression by regulating CCAR1. Furthermore, in vivo experiments in mice demonstrated that silencing circTUBD1 inhibits the proliferation and metastasis of LSCC.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This study provides evidence that circTUBD1 is a potential tumor marker for LSCC and underscores the therapeutic potential of targeting circTUBD1 in this cancer type.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70834","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70834","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Laryngeal squamous cell carcinoma (LSCC) is one of the most prevalent malignancies of the head and neck region. Circular RNAs (circRNAs) have been found to exhibit abnormal expression patterns in various tumors and play pivotal roles in tumorigenesis and tumor progression.

Methods

Functional assays assessed proliferation, migration, and invasion. Mechanistic studies were performed to explore the interaction between circTUBD1 and heterogeneous nuclear ribonucleoprotein K (hnRNPK), as well as its regulation of Cell Cycle and Apoptosis Regulator 1 (CCAR1). In vivo experiments confirmed circTUBD1's role in tumor growth and metastasis.

Results

We discovered that circTUBD1 is significantly upregulated in LSCC and promotes the proliferation, invasion, and migration of LSCC cells. circTUBD1 forms a circRNA-protein complex with hnRNPK and facilitates LSCC progression by regulating CCAR1. Furthermore, in vivo experiments in mice demonstrated that silencing circTUBD1 inhibits the proliferation and metastasis of LSCC.

Conclusions

This study provides evidence that circTUBD1 is a potential tumor marker for LSCC and underscores the therapeutic potential of targeting circTUBD1 in this cancer type.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.